These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23844082)

  • 1. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression.
    Gil-Fariña I; Di Scala M; Vanrell L; Olagüe C; Vales A; High KA; Prieto J; Mingozzi F; Gonzalez-Aseguinolaza G
    PLoS One; 2013; 8(7):e67748. PubMed ID: 23844082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis.
    Hsueh YH; Chen HW; Syu BJ; Lin CI; Leung PSC; Gershwin ME; Chuang YH
    J Autoimmun; 2018 Dec; 95():159-170. PubMed ID: 30274824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.
    Lisowski L; Dane AP; Chu K; Zhang Y; Cunningham SC; Wilson EM; Nygaard S; Grompe M; Alexander IE; Kay MA
    Nature; 2014 Feb; 506(7488):382-6. PubMed ID: 24390344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
    Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
    Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
    Mays LE; Wilson JM
    Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.
    Martino AT; Suzuki M; Markusic DM; Zolotukhin I; Ryals RC; Moghimi B; Ertl HC; Muruve DA; Lee B; Herzog RW
    Blood; 2011 Jun; 117(24):6459-68. PubMed ID: 21474674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.
    Davidoff AM; Gray JT; Ng CY; Zhang Y; Zhou J; Spence Y; Bakar Y; Nathwani AC
    Mol Ther; 2005 Jun; 11(6):875-88. PubMed ID: 15922958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
    Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
    Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
    Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
    Mueller C; Chulay JD; Trapnell BC; Humphries M; Carey B; Sandhaus RA; McElvaney NG; Messina L; Tang Q; Rouhani FN; Campbell-Thompson M; Fu AD; Yachnis A; Knop DR; Ye GJ; Brantly M; Calcedo R; Somanathan S; Richman LP; Vonderheide RH; Hulme MA; Brusko TM; Wilson JM; Flotte TR
    J Clin Invest; 2013 Dec; 123(12):5310-8. PubMed ID: 24231351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
    Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
    Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing transduction of the liver by adeno-associated viral vectors.
    Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
    Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.
    Hösel M; Huber A; Bohlen S; Lucifora J; Ronzitti G; Puzzo F; Boisgerault F; Hacker UT; Kwanten WJ; Klöting N; Blüher M; Gluschko A; Schramm M; Utermöhlen O; Bloch W; Mingozzi F; Krut O; Büning H
    Hepatology; 2017 Jul; 66(1):252-265. PubMed ID: 28318036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
    Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
    Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Existing Immunity to a Nucleic Acid Contaminant-Derived Antigen Mediates Transaminitis and Resultant Diminished Transgene Expression in a Mouse Model of Hepatic Recombinant Adeno-Associated Virus-Mediated Gene Transfer.
    Brimble MA; Morton CL; Winston SM; Reeves IL; Spence Y; Cheng PH; Zhou J; Nathwani AC; Thomas PG; Souquette A; Davidoff AM
    Hum Gene Ther; 2024 Jul; 35(13-14):477-489. PubMed ID: 38420654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.
    Wang L; Figueredo J; Calcedo R; Lin J; Wilson JM
    Hum Gene Ther; 2007 Mar; 18(3):185-94. PubMed ID: 17324107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
    McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
    Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.